Skip to main content

Cognitive enhancers for ageing and Alzheimer's disease

Edited by Howard Fillit

This series of articles, published in Alzheimer's Research & Therapy, has not been sponsored. All articles have undergone the journal’s standard peer review process overseen by the Series Editor, with final decisions made by the Editors in Chief. The Series Editor and Editors in Chief declare no competing interests.

  1. Increased knowledge of the biology of synaptic function has led to the development of novel cognitive-enhancing therapeutic strategies with the potential for increased efficacy and safety. This editorial highl...

    Authors: Diana W Shineman, Aaron J Carman, Penny A Dacks, Rachel F Lane and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2013 5:45
  2. Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has ge...

    Authors: Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta and David Schubert
    Citation: Alzheimer's Research & Therapy 2013 5:25
  3. The Alzheimer's disease (AD) epidemic is a looming crisis, with an urgent need for new therapies to delay or prevent symptom onset and progression. There is growing awareness that clinical trials must target s...

    Authors: Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker and Allan I Levey
    Citation: Alzheimer's Research & Therapy 2013 5:21
  4. During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition. Several studies with structurally different compounds have shown that not only...

    Authors: María Javier Ramírez
    Citation: Alzheimer's Research & Therapy 2013 5:15